Effects of Camrelizumab combined with Lenvatinib mesylate in treatment of patients with middle-advanced hepatocellular carcinoma
Objective:To observe effects of Camrelizumab combined with Lenvatinib mesylate in treatment of patients with middle-advanced hepatocellular carcinoma.Methods:A prospective study was conducted on 86 patients with middle-advanced hepatocellular carcinoma admitted to this hospital from December 2021 to December 2022.They were divided into control group(n=43)and observation group(n=43)by using the random number table method.The control group was treated with Lenvatinib mesylate,while the observation group was treated with Camrelizumab on the basis of that of the control group.The objective response rate(ORR),the liver function indexes[alanine aminotransferase(ALT),alkaline phosphatase(ALP),total bilirubin(TBIL),aspartate aminotransferase(AST)]levels before and after the treatment,the serological indexes[soluble vascular cell adhesion factor 1(sVCAM1),vascular endothelial growth factor(VEGF)]levels,and the incidence of adverse reactions were compared between the two groups.Results:The ORR of the observation group was 69.77%(30/43),which was higher than 48.84%(21/43)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of ALT,AST,TBIL,ALP,VEGF and sVCAM1 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Camrelizumab combined with Lenvatinib mesylate in the treatment of the patients with middle-advanced= hepatocellular carcinoma can improve the ORR,reduce the levels of liver function indexes and serological indexes.Moreover,it is superior to single Lenvatinib mesylate treatment.
万方数据
维普
